within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03D_Progestogens.G03DB01_Dydrogesterone;

model Dydrogesterone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.28,
    Cl = 1.777777777777778e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.054,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dydrogesterone</td></tr><tr><td>ATC code:</td><td>G03DB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>54</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dydrogesterone is a synthetic progestogen, structurally related to progesterone, used in hormone replacement therapy, luteal phase support, management of various gynecological disorders such as dysmenorrhea, irregular menstrual cycles, endometriosis, and secondary amenorrhea. It is approved and in clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult female volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Neumann, K, et al., &amp; Griesinger, G (2022). Dydrogesterone and 20α-dihydrodydrogesterone plasma levels on day of embryo transfer and clinical outcome in an anovulatory programmed frozen-thawed embryo transfer cycle: a prospective cohort study. <i>Human reproduction (Oxford, England)</i> 37(6) 1183–1193. DOI:<a href=\"https://doi.org/10.1093/humrep/deac045\">10.1093/humrep/deac045</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35323905/\">https://pubmed.ncbi.nlm.nih.gov/35323905</a></p></li><li><p>Christin-Maitre, S, et al., &amp; Reginster, JY (2003). Pharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathways. <i>The Journal of clinical endocrinology and metabolism</i> 88(11) 5405–5413. DOI:<a href=\"https://doi.org/10.1210/jc.2003-030094\">10.1210/jc.2003-030094</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14602781/\">https://pubmed.ncbi.nlm.nih.gov/14602781</a></p></li><li><p>Cucinelli, F, et al., &amp; Lanzone, A (1999). Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. <i>European journal of endocrinology</i> 140(3) 215–223. DOI:<a href=\"https://doi.org/10.1530/eje.0.1400215\">10.1530/eje.0.1400215</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10216516/\">https://pubmed.ncbi.nlm.nih.gov/10216516</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G03DB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dydrogesterone;
